DekaBank Deutsche Girozentrale Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

DekaBank Deutsche Girozentrale increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 221,718 shares of the company’s stock after buying an additional 27,705 shares during the period. DekaBank Deutsche Girozentrale owned about 0.06% of Moderna worth $24,697,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its holdings in Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after buying an additional 187 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after purchasing an additional 381,808 shares in the last quarter. abrdn plc lifted its holdings in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in shares of Moderna in the fourth quarter valued at about $1,358,000. Finally, Hobbs Group Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at about $664,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 8.1 %

Shares of Moderna stock traded down $7.59 during trading hours on Friday, hitting $86.58. The company’s stock had a trading volume of 10,332,912 shares, compared to its average volume of 3,496,157. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The business has a fifty day moving average of $129.81 and a 200 day moving average of $115.11. The company has a market capitalization of $33.18 billion, a PE ratio of -5.53 and a beta of 1.67. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the prior year, the business earned ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. As a group, equities analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 202,832 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the sale, the director now directly owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Noubar Afeyan sold 202,832 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the transaction, the director now owns 1,528,557 shares in the company, valued at $226,746,145.38. The disclosure for this sale can be found here. Insiders sold 396,239 shares of company stock valued at $55,563,937 over the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

MRNA has been the topic of several recent research reports. Canaccord Genuity Group upped their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Finally, Royal Bank of Canada reduced their price objective on shares of Moderna from $160.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $126.59.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.